Intellia Therapeutics Inc (NTLA)
R&D Expense Growth
2.30%
Quarterly · Period ending:
NTLA R&D Expense Growth
Latest reported2.30%period ending
Latest reported2.30%period ending
NTLA Quarterly R&D Growth (QoQ) (0.00% → 2.30%)
Latest values, visible window
High-resolution chart · PNG
NTLA r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 2.3013% | |
| -8.9282% | |
| -6.4329% | |
| -2.3579% | |
| -10.5066% | |
| -7.2298% | |
| -5.2707% | |
| 10.5476% | |
| 2.0789% | |
| 0.3248% | |
| -4.147% | |
| -1.3706% | |
| 18.6993% | |
| -2.917% | |
| 3.5002% | |
| 7.1531% | |
| -32.2296% | |
| 87.0336% | |
| 17.6487% | |
| 2.7206% | |
| 49.9236% | |
| 2.7334% | |
| -3.8359% | |
| 5.2554% | |
| 9.0072% | |
| 9.1992% | |
| 15.3309% | |
| 8.0636% | |
| 7.3854% | |
| 19.033% | |
| -14.2833% | |
| -0.9801% | |
| 4.3302% | |
| 6.2494% | |
| 21.1029% | |
| 12.3097% | |
| 15.8886% | |
| 18.5332% | |
| 44.142% | |
| 5.9006% | |
| 42.067% | |
| 19.4286% | |
| 26.5182% | |
| 75.8901% | |
| 43.399% | |
| -69.5469% | |
| 0% | |
| 0% |